Table 1.

Risk stratification models for endometrial cancers.

ESMO-ESGO-ESTRO consensus guidelines (Colombo et al)6
Method of evaluation	High-risk factors	Low-risk factors	Non–low-risk factors	Purpose of triage
EB, preoperative MRI	EB: Non-endometrioid histology, FIGO G3, LVSI Imaging: MI >50%, cervical involvement	Stage I, endometrioid, G1–2 LVSI –ve, <50% MI	Anything more than low risk	Omitting lymphadenectomy and adjuvant therapy
Korean Gynecologic oncology group (KGOG) guidelines (Kang et al)8
EB, serum Ca 125, preoperative MRI	Non-endometrioid histology, Ca 125 > 35 mIU/mL, MI, high-volume index of tumor, extrauterine disease	Stage I, endometrioid, Ca 125 < 35, low-volume index	Anything more than low risk	Selective lymphadenectomy
Mayo Clinic protocol (Mariani et al)3
Intraoperative examination (IOE), peritoneal cytology, frozen section (FS)	Non-endometrioid histology, grade, MI, cervical involvement, extrauterine disease	Endometrioid histology, G1–2, stage I, MI <50%, PTD <2 cm OR endometrioid, stage I, no MI (irrespective of grade/PTD)	Anything more than low risk	Omission of lymphadenectomy
Modified Mayo Clinic criteria (used in this study)
Endometrial biopsy: Histology grade Imaging: Preoperative MRI and 18F-FDG PET–CT scan	Non-endometrioid histology, G3, MI >50%, tumor diameter (TD) >2 cm, cervical involvement, LN disease, extrauterine disease	Endometrioid histology, G1–2, stage I, TD< 2 cm, MI <50%, no cervical or extrauterine spread, no LN disease	Anything more than low risk	Presurgical triage into low-risk and non–low-risk groups

EB, endometrial biopsy; MRI, magnetic resonance imaging; MI, myometrial invasion; LN, lymph node.; ESMO, European Society of Medical Oncology; ESGO, European society of Gynecological Oncology; ESTRO, European Society of Radiotherapy and Oncology; FIGO, International Federation of Gynecology and Obstetrics; LVSI, Lymph Vascular Space Invasion; PTD, Primary Tumor Diameter; ₁₈ F FDG - PET-CT , ₁₈ F Fluorodeoxyglucose Positron Emission Tomography - Computerised Tomography.